This document summarizes the key points about acute decompensated heart failure (ADHF):
- ADHF accounts for most of the $39 billion spent annually on treating heart failure in the US. It results from exacerbations of chronic cardiac, pulmonary, or renal dysfunction.
- Standard pharmacotherapy for ADHF includes diuretics to treat fluid overload and vasodilators or inotropes to treat low cardiac output, guided by the patient's Forrester hemodynamic subset classification.
- The goals of ADHF treatment are to improve symptoms, optimize volume status, identify precipitating factors, and optimize chronic oral therapy to prevent readmissions and reduce costs. Multidisciplinary care including pharmacists improves outcomes
Role of Clinical Pharmacist in Management of Congestive Heart Failure – A Bri...BRNSS Publication Hub
Heart failure (HF) is a clinical condition occurs when cardiac output is insufficient to meet the demands of tissue perfusion or does so by elevating filling pressure. HF is due to either systolic or diastolic dysfunction which reduces ventricular filling (diastolic dysfunction) and/or myocardial contractility (systolic dysfunction). Clinically, cardiac disease prevalence increases with individual age. Cardiac dysfunction occurs due to change in blood volume, and neurohumoral transmission status these desirable mechanisms to maintain adequate cardiac output and arterial blood pressure. The activation of three compensatory neurohormonal systems triggers the cardiac dysfunction leads to HF. Clinical pharmacist plays a role in disease management by identifying the risk factors, stage of severity, educating the patients and health-care practitioners and implementing the awareness programs, and modification of lifestyle interventions with in health-care system beneficial to the community may reduce the progression of disease severity.
Pulmonary Arterial Hypertension (PAH): A Rare & Progressive DisorderKumaraguru Veerasamy
In this SlideShare, we provide an overview on PAH, short for pulmonary arterial hypertension, a rare and progressive disorder caused by the obstruction in the smaller arteries within the lungs. This raises the blood pressure, forcing the heart to work harder. PAH is one of 5 groups classifications by the WHO. The slides briefly covers the symptoms, diagnosis and potential treatments for PAH patients, including those by Aria CV and Liquidia.
Role of Clinical Pharmacist in Management of Congestive Heart Failure – A Bri...BRNSS Publication Hub
Heart failure (HF) is a clinical condition occurs when cardiac output is insufficient to meet the demands of tissue perfusion or does so by elevating filling pressure. HF is due to either systolic or diastolic dysfunction which reduces ventricular filling (diastolic dysfunction) and/or myocardial contractility (systolic dysfunction). Clinically, cardiac disease prevalence increases with individual age. Cardiac dysfunction occurs due to change in blood volume, and neurohumoral transmission status these desirable mechanisms to maintain adequate cardiac output and arterial blood pressure. The activation of three compensatory neurohormonal systems triggers the cardiac dysfunction leads to HF. Clinical pharmacist plays a role in disease management by identifying the risk factors, stage of severity, educating the patients and health-care practitioners and implementing the awareness programs, and modification of lifestyle interventions with in health-care system beneficial to the community may reduce the progression of disease severity.
Pulmonary Arterial Hypertension (PAH): A Rare & Progressive DisorderKumaraguru Veerasamy
In this SlideShare, we provide an overview on PAH, short for pulmonary arterial hypertension, a rare and progressive disorder caused by the obstruction in the smaller arteries within the lungs. This raises the blood pressure, forcing the heart to work harder. PAH is one of 5 groups classifications by the WHO. The slides briefly covers the symptoms, diagnosis and potential treatments for PAH patients, including those by Aria CV and Liquidia.
Chronic Obstructive Pulmonary Disease and Heart Failure The challenges facin...magdy elmasry
Chronic Obstructive Pulmonary Disease and Heart Failure
The challenges facing cardiologists and pulmonologists,
prevalence of heart failure in COPD patients .Association of Cardiovascular Disease With Respiratory Disease,An atypical presentation of myocardial infarction (MI) should be considered in every patient presenting with COPD exacerbation ,Cardiovascular and pulmonary disease in the context of inflammation
(“CardioPulmonary Continuum”),The cornerstones of therapy are beta-blockers and beta-agonists ,which as their modes of action suggest oppose each other’s action
This presentation covers the methodology of evaluating CTEPH (chronic thromboembolic pulmonary hypertension) case. It starts from the basic concepts of Pulmonary hypertension.
Market Research Reports, Inc. has announced the addition of “Pulmonary Arterial Hypertension - Pipeline Review, H2 2017” research report to their offering. See more at - http://mrr.cm/UHD
PowerPoint presentation describing various aspects of Pulmonary Hypertension. Please mail me your feedback on this presentation to following Email ID: tinkujoseph2010@gmail.com.
Chronic Obstructive Pulmonary Disease and Heart Failure The challenges facin...magdy elmasry
Chronic Obstructive Pulmonary Disease and Heart Failure
The challenges facing cardiologists and pulmonologists,
prevalence of heart failure in COPD patients .Association of Cardiovascular Disease With Respiratory Disease,An atypical presentation of myocardial infarction (MI) should be considered in every patient presenting with COPD exacerbation ,Cardiovascular and pulmonary disease in the context of inflammation
(“CardioPulmonary Continuum”),The cornerstones of therapy are beta-blockers and beta-agonists ,which as their modes of action suggest oppose each other’s action
This presentation covers the methodology of evaluating CTEPH (chronic thromboembolic pulmonary hypertension) case. It starts from the basic concepts of Pulmonary hypertension.
Market Research Reports, Inc. has announced the addition of “Pulmonary Arterial Hypertension - Pipeline Review, H2 2017” research report to their offering. See more at - http://mrr.cm/UHD
PowerPoint presentation describing various aspects of Pulmonary Hypertension. Please mail me your feedback on this presentation to following Email ID: tinkujoseph2010@gmail.com.
Cardiology: Treatment of Heart FailureVedica Sethi
Abstract Heart Failure (HF) is the most widely recognized cardiovascular disorder behind medical clinic affirmation for individuals more established than 60 years old. Hardly any regions in medication have advanced as surprisingly as HF treatment in the course of recent decades. Be that as it may, progress has been reliable just for ceaseless HF with diminished discharge part. In intensely decompensated HF and HF with safeguarded discharge part, none of the medications tried to date have been conclusively demonstrated to improve endurance. Deferring or forestalling HF has gotten progressively significant in patients who are inclined to HF. The anticipation of declining interminable HF and hospitalisations for intense decompensation is likewise critical. The target of this paper is to give a compact and down to earth rundown of the accessible medication medicines for HF. The most ideal proof based medication treatment (counting inhibitors of the renin–angiotensin– aldosterone framework and β blockers) is helpful just when ideally actualized. Notwithstanding, usage may be testing. To accept that ailment the executives projects can be useful in giving a multidisciplinary, comprehensive way to deal with the conveyance of ideal clinical consideration. Keywords; heart failure, multidisciplinary approach, Beat-blocker, RAAS framework
A novel approach to medical management of heart failure with reduced ejectionRamachandra Barik
The advent of newly available medical therapies for HFrEF has resulted in many potential therapeutic combinations, increasing treatment complexity. Publication of expert consensus guidelines and initiative aimed to improve treatment implementation have emphasized sequential, stepwise initiation and titration of medical therapy, which is labour intensive. Data taken from heart failure registries shows suboptimal use of medications, prolonged titration time and consequently little change in dose intensity, all of which, indicate therapeutic inertia. Recently published evidence indicates that four medication classes (1. renin-angiotensin-neprilysin inhibitors, 2. beta-blockers, 3. mineralocorticoid antagonists and 4. sodium-glucose cotransporter inhibitors), which we refer to as Foundational Therapy, confer rapid and robust reduction in both morbidity and mortality in most patients with HFrEF, and that they work in additive fashion. Additional morbidity and/or mortality may be observed following addition of several Personalized Therapies in specific subgroups of patients. In this review, we discuss mechanisms of action of these therapies and propose a framework for their implementation based on several principles. These include the critical importance of rapid initiation of all 4 Foundational Therapies followed by their titration to target doses, emphasis on multiple simultaneous drug changes with each patient encounter, attention to patient-specific factors in choice of medication class, leveraging inpatient care, use of the entire health care team and alternative (i.e. virtual visits) modes of care. We have incorporated these principles into a ‘Cluster Scheme’ designed to facilitate timely and optimal medical treatment for patients with HFrEF.
Introduction
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Acute Decompersated Heart Failure
1. 10/22/13 www.medscape.com/viewarticle/780685_print
www.medscape.com/viewarticle/780685_print 1/8
www.medscape.com
Abstract and Introduction
Abstract
Acute decompensated heart failure (ADHF), an exacerbation of chronic cardiac, pulmonary, and/or renal
dysfunction, accounts for most of the $39 billion spent on chronic heart failure. The pharmacotherapy of ADHF
has not changed recently, but studies have indicated that most therapy is efficaciously, though not economically,
equivalent. Evidence-based, inpatient pharmacotherapy is guided by understanding of the Forrester Hemodynamic
subsets and their pathophysiology. Clinical success is dependent not only upon proper inpatient treatment, but
also upon the utilization of a discharge team. Pharmacists can bridge the gap between hospital visits and
outpatient care by recommending and providing continuity of care.
Introduction
In 2010, the cost of treating heart failure (HF) in the United States was estimated at $39.2 billion.[1,2] Nearly 1
million patients are hospitalized each year for exacerbations, and HF currently ranks as the most common reason
for hospital admission in adults over 65 years of age.[2] Acute decompensated heart failure (ADHF) can result from
poorly controlled, chronic HF and/or cardiac, pulmonary, or renal dysfunction. The inpatient cost of care for these
patients is extremely high, accounting for about 60% of total HF expenditures.[3]
In addition to the financial impact of HF, longevity and quality of life are severely impacted in patients with acute
exacerbations. Hospital admission is associated with an increased risk of mortality in HF patients; mortality
occurs in 15.5% of patients, and one-third of patients are never discharged from the hospital.[2] ADHF is a
crippling disease burdening not just patients, but also the health care system.
ADHF pharmacotherapy is a battleground for hospitals seeking to control costs in an era of reduced payments
and increased expenses. In October 2012, the Centers for Medicare and Medicaid (CMS) began cutting
reimbursements to hospitals with high rates of patient readmissions in three high-cost disease states: myocardial
infarction (MI), pneumonia, and HF. If patients with these conditions are readmitted within 30 days, CMS will
reduce total base reimbursement by 1% annually, until a maximum 3% reduction by 2014.[4] Soon, financial loss
will motivate the nearly 2,000 hospitals suffering the highest penalties to institute new policies and follow-up care
for patients discharged with a diagnosis of HF.
Fortunately, a 2011 analysis by CMS showed that the rate of HF admissions had actually decreased over a 10-
year period.[1] In 2008, there were 229,000 fewer admissions than expected given observed trends over the past
several decades.[1,5] Researchers attributed this decline to "reductions in the incidence of coronary artery
disease, improved control of blood pressure, increased use of evidence-based therapies, and possibly changes in
admission thresholds." The rate of 1-year all-cause mortality, however, remained high at approximately 30% for
patients hospitalized due to HF.[1,5] Black males and certain regions in the country fared worse in rates of
hospitalization; researchers hypothesized that differences in accessibility or quality of care could contribute to
this disparity.[1] The best outcomes (reduced costs and readmission rates) are seen with a multidisciplinary
approach that includes physicians, pharmacists, nurses, nutritionists, and physical therapists.[6] This article is a
brief review of ADHF pharmacotherapy with an additional look at pharmacoeconomic considerations and discharge
controversies.
Pathophysiology
ADHF is defined as a sudden worsening of HF symptoms and is usually caused by cardiogenic pulmonary edema
with rapid fluid accumulation in the lungs, although it can occur without pulmonary edema.[7] Hypertension,
Acute Decompensated Heart Failure
John A. Galdo, PharmD, BCPS, Ashlee Rickard Riggs, PharmD, Amy L. Morris,
PharmD Candidate
US Pharmacist. 2013;38(2):HS-2-HS-8.
2. 10/22/13 www.medscape.com/viewarticle/780685_print
www.medscape.com/viewarticle/780685_print 2/8
ischemia, and/or ventricular dysfunction causes a decrease in cardiac output, which leads to an activation of the
neurohormonal pathway. The sympathetic system increases norepinephrine to improve peripheral perfusion via
vasoconstriction and activates the renin-angiotensin-aldosterone system to increase renal perfusion through water
retention.[8] An acute increase in left ventricular filling pressure causes protein-poor fluid to leak into the lung
alveoli and interstitium, but no compromise of pulmonary membrane integrity occurs. Compensatory mechanisms
increase heart rate and systemic vascular resistance in an attempt to improve cardiac output, and a vicious cycle
ensues.[7,8]
Common causes of ADHF include left ventricular or diastolic dysfunction with or without coronary artery disease
(CAD) or valvular abnormalities. Although most patients hospitalized with ADHF have a worsening of preexisting
HF, up to 20% of patients have no prior diagnosis of HF.[9]
ADHF can also occur in patients without any preexisting cardiac disease, including conditions such as severe
hypertension, fluid overload, severe renal disease, or renal artery stenosis. Factors precipitating an event involve a
change in the flow of blood through the heart; ADHF can be induced by hypertensive crisis, MI or ischemia, atrial
obstruction, acute mitral regurgitation, fluid overload, or nonadherence to HF medications. Certain medications,
such as beta-blockers, nondihydropyridine calcium channel blockers, and nonsteroidal anti-inflammatory drugs
(NSAIDs), can also precipitate ADHF.[7,10]
Classification
ADHF can be categorized into hemodynamic stages depending on cardiac index and pulmonary capillary wedge
pressure. The stages are classified as the Forrester Hemodynamic subsets ().[11] Cardiac index (CI) indicates the
degree of perfusion; patients are characterized as either "warm" or "cold" depending on the presence of
hypoperfusion. A CI of <2.2 L/min/m2 warrants a classification of "cold," indicating hypoperfusion. Signs and
symptoms consistent with hypoperfusion include fatigue, hypotension, cool extremities, decreased renal function,
and altered mental status. Pulmonary capillary wedge pressure (PCWP) indicates fluid status; patients are
classified as either "dry" or "wet" depending on the presence of edema, which is defined as a PCWP >18 mmHg.
Signs and symptoms of volume overload include cough, dyspnea, paroxysmal nocturnal dyspnea, elevated jugular
venous pressure, peripheral edema, ascites, hepatomegaly, and splenomegaly.
Table 1. Forrester Hemodynamic Subsets
Subset Description
I: Warm and dry (normal) PCWP 15–18 mmHg and CI >2.2 L/min/m2
II: Warm and wet (congestion) PCWP >18 mmHg and CI >2.2 L/min/m2
III: Cold and dry (hypoperfusion) PCWP 15–18 mmHg and CI <2.2 L/min/m2
IV: Cold and wet (congestion and hypoperfusion) PCWP >18 mmHg and CI <2.2 L/min/m2
CI: cardiac index; PCWP: pulmonary capillary wedge pressure. Source: Reference 11.
The most common presentation, constituting two-thirds of ADHF admissions, is subset II (warm and wet).[8] In
comparison to subset I (warm and dry), subset IV (cold and wet) increases the rate of death by two and one-half
times.[12] Three key laboratory parameters indicate an increased risk of inpatient mortality according to the Acute
Decompensated Heart Failure National Registry (ADHERE) trial: a blood urea nitrogen of ≥43 g/dL, systolic blood
pressure <115 mmHg, and/or serum creatinine >2.75 mg/dL.[13]
Pharmacotherapy
Pharmacologic management of ADHF is guided by the patient's hemodynamic status, which is evaluated using CI
and PCWP values ().[11] The goals and medications for treatment of ADHF are summarized in and .[8,14–16] While
the standard of care has not changed significantly over the past several years, a new focus on the
pharmacoeconomic impact of HF has shown that not all treatments are equal. Pharmacotherapy should be
3. 10/22/13 www.medscape.com/viewarticle/780685_print
www.medscape.com/viewarticle/780685_print 3/8
chosen based on the diagnosed subset, either treating fluid overload or hypoperfusion. Patients in subset IV are
classified as having both fluid overload and perfusion dysfunction and, therefore, require therapy for both
symptoms.
Table 1. Forrester Hemodynamic Subsets
Subset Description
I: Warm and dry (normal) PCWP 15–18 mmHg and CI >2.2 L/min/m2
II: Warm and wet (congestion) PCWP >18 mmHg and CI >2.2 L/min/m2
III: Cold and dry (hypoperfusion) PCWP 15–18 mmHg and CI <2.2 L/min/m2
IV: Cold and wet (congestion and hypoperfusion) PCWP >18 mmHg and CI <2.2 L/min/m2
CI: cardiac index; PCWP: pulmonary capillary wedge pressure. Source: Reference 11.
Table 2. Treatment Goals for ADHF
1. Improve symptoms, especially congestion and low-output symptoms
2. Restore normal oxygenation
3. Optimize volume status
4. Identify etiology
5. Identify and address precipitating factors
6. Optimize chronic oral therapy
7. Minimize side effects
8. Identify patients who might benefit from revascularization
9. Identify patients who might benefit from device therapy
10. Identify risk of thromboembolism and need for anticoagulation
11. Educate patients concerning medications and self-management of heart failure
12. Consider and, where possible, initiate a disease-management program
ADHF: acute decompensated heart failure.
Source: References 8, 14–16.
Table 3. Pharmacotherapy for ADHF
Subset I: Warm and Dry
Therapy is the optimization of oral medications
Subset II: Warm and Wet
Patient has hypervolemia
4. 10/22/13 www.medscape.com/viewarticle/780685_print
www.medscape.com/viewarticle/780685_print 4/8
IV diuretics and plus or minus vasodilators, nesiritide
Subset III: Cold and Dry
Patient has hypoperfusion
Therapy:
If PCWP <15 mmHg, IV fluids until PCWP 15–18 mmHg
If PCWP ≥15 mmHg and MAP <50 mmHg, IV dobutamine
If PCWP ≥15 mmHg, MAP ≥50 mmHg and compelling indication for inotrope, IV inotrope
IF PCWP ≥15 mmHg, MAP ≥50 mmHg and no compelling indication for inotrope, IV vasodilator
Subset IV: Cold and Wet
Patient has hypoperfusion and hypervolemia
Therapy:
IV diuretics
If MAP <50 mmHg, IV dobutamine
If MAP ≥50 mmHg and compelling indication for inotrope, IV inotrope
If MAP ≥50 mmHg and no compelling indication for inotrope, IV vasodilator
ADHF: acute decompensated heart failure; MAP: mean arterial pressure; PCWP: pulmonary capillary wedge
pressure.
Source: References 8, 14–16.
Subset II or IV—Wet
Intravenous (IV) loop diuretics are the mainstay of ADHF treatment for patients presenting with fluid overload
(PCWP >18 mmHg), despite conflicting data regarding mortality and morbidity benefit. A meta-analysis of 14
small trials showed decreased mortality and hospitalizations in diuretic-treated patients;[17] however, a recent
analysis of observational data from the ADHERE trial showed that hospitalized patients treated with IV diuretics
had a longer overall length of stay and a longer ICU length of stay.[18] Regardless, the 2009 focused update of the
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of HF
recommends early administration of IV diuretics.[14] Bolus doses of loop diuretics are preferred. Furosemide is
most commonly used; however, bumetanide and torsemide are equally efficacious. If patients have inadequate
response to the maximum recommended bolus dose of a loop diuretic, continuous infusion of furosemide may be
started at 5 mg/h and titrated to 20 mg/h as needed.[14]
The superiority of administering furosemide as continuous infusion has yet to be established; the Diuretic
Optimization Strategies Evaluation (DOSE) trial, which studied 308 hospitalized patients randomized to receive
either bolus or IV furosemide, did not show a significant difference between safety and efficacy endpoints, but
smaller studies have indicated a small increase in urinary output with continuous infusion.[19] The unmanaged
effects of rapid diuresis, such as electrolyte imbalances and renal dysfunction, may lead to prolonged
hospitalization beyond the resolution of ADHF symptoms, so electrolytes and serum creatinine should be
monitored frequently.
5. 10/22/13 www.medscape.com/viewarticle/780685_print
www.medscape.com/viewarticle/780685_print 5/8
Another strategy to increase diuresis is to add a second diuretic with a different mechanism of action such as
metolazone or spironolactone. Metolazone, a thiazide-like diuretic, is utilized most frequently for acute volume
control; however, spironolactone and other aldosterone antagonists are preferred in chronic HF therapy.[20–22]
In patients with continued hypertension and/or persistent symptoms despite aggressive diuresis, a vasodilator
may be added to reduce pulmonary congestion. Sodium nitroprusside, nesiritide, and IV nitroglycerin are venous
vasodilators that quickly relieve congestive symptoms by reducing PCWP. If a patient presents with low cardiac
output and high systemic vascular resistance, venous vasodilators or inotropes are recommended, although
vasodilators are the preferred therapy. Due to the risk of cyanide toxicity from prolonged, high-dose infusions of
nitroprusside, the preferred vasodilators are nesiritide and nitroglycerin. Of the two, nesiritide produced a greater
improvement in global clinical status over nitroglycerin in the Vasodilation in the Management of Acute Congestive
Heart Failure (VMAC) trial despite the drug's propensity to cause hypotension.[13] Therefore, nesiritide is the
preferred agent in a patient with fluid overload and low cardiac output.
The utility of nesiritide has been questioned because of its high acquisition cost.[23] Clinical outcomes data are
lacking, but one pharmacoeconomic model shows that the high initial cost of nesiritide is offset by the lower rate
of hospital readmission within 21 days when compared to patients who received dobutamine.[24] Similarly, a
retrospective analysis of ADHERE data showed that patients treated with nitroglycerin or nesiritide were
discharged from the hospital sooner than patients treated with dobutamine or milrinone and also had a lower
mortality risk.[13] Since more critically ill patients were treated with inotropes, it is difficult to attribute the
incidence of increased mortality to the drug.
Subset III or IV—Cold
Dobutamine and milrinone are the inotropes of choice to increase perfusion and preserve end-organ perfusion in
patients with decreased cardiac output. Compelling indications for inotropes include systolic blood pressure <90
mmHg, symptomatic hypotension despite adequate filling pressures (PCWP 15–18 mmHg), worsening renal
function, or inadequate response to IV vasodilators. Prudent selection of patients is necessary because data
suggest poor outcomes occur when inotropes are given to patients with preserved cardiac output. The OPTIME-
CHF trial showed a nonsignificant increase in mortality and arrhythmias when milrinone infusions were given to
patients as a part of standard care.[25] Milrinone should be chosen to treat patients receiving concomitant beta-
blockers since it exerts an effect on cardiac output and systemic vascular resistance via phosphodiesterase
inhibition, whereas dobutamine is a beta1 agonist. Dobutamine, however, is the best choice for hypotensive
patients, as milrinone can cause significant drops in blood pressure.[15]
Discharge Planning
The final step in the treatment of ADHF is discharge planning and follow-up. Both the ACC/AHA and the Heart
Failure Society of America (HFSA) guidelines advocate the importance of proper discharge planning.[14,15]
Mainstays of evidence-based discharge care include treating exacerbating factors, such as discontinuing
nondihydropyridine calcium channel blockers or NSAIDs, achieving optimal volume state, optimizing
pharmacologic therapy, and transitioning to outpatient oral therapy ().[15] The ACC/AHA guidelines recommend
giving written instructions or educational material to patients and/or caregivers at discharge addressing the
following: activity level, diet, discharge medications, follow-up appointment, weight monitoring, and what to do if
symptoms worsen.[14] Guidelines also indicate the benefit of initiating mortality-lowering oral therapy for HF during
hospital admission, such as angiotensin-converting enzyme (ACE) inhibitors and beta-blockers. Studies show
that guideline-based care decreases mortality,[26] but fails to show reduction in readmission rates for patients with
HF.[27,28]
Table 4. Discharge Criteria for Patients With ADHF
Treat exacerbating factors (i.e., discontinuation of contraindicated medications)
Patient is at a "dry" weight
6. 10/22/13 www.medscape.com/viewarticle/780685_print
www.medscape.com/viewarticle/780685_print 6/8
Oral medication regimen stable for 24 hours
Patient and family education completed, including clear discharge instructions
Left ventricular ejection fraction documented
Smoking cessation counseling initiated
Follow-up clinic visit scheduled, 7 to 10 days out
Optimal pharmacologic therapy achieved or intolerance documented
Plans for postdischarge management
ADHF: acute decompensated heart failure. Source: Reference 15.
Discharge support, or hospital-based case management, is now being utilized for discharge planning. Discharge
support is a multidisciplinary, team-based approach to care that deals with medication support, patient education,
follow-up planning, and coordination of information. A meta-analysis of 18 randomized, controlled trials (RCT)
analyzing discharge planning with postdischarge support involving 3,304 patients found a significant reduction in
all-cause readmissions (relative risk [RR] 0.75, 95% CI 0.68–0.88).[29] The external validity of the meta-analysis is
difficult to determine but may offer some cost-effective strategies. One strategy is from an RCT of 223 HF patients
that compared traditional discharge support with educational materials to a 1-hour, one-on-one teaching session
with a nurse educator prior to discharge.[30] The nurse intervention group had lower risks of rehospitalization or
death 180 days after discharge and was estimated to save $2,823 per patient. Conversely, large-scale
observational studies have found no relationship between patients receiving educational materials and decreased
readmission rates.[26,31] Current ACC/AHA guidelines do not explicitly state how to discharge patients after
ADHF other than by giving educational materials.[14] Guideline recommendations may not provide discharge
procedures that help hospitals comply with CMS expectations.
While educational materials at discharge did not show a mortality benefit, each additional oral agent used for the
treatment of HF, such as a beta-blocker or aldosterone antagonist, can decrease hospitalizations and/or mortality
by 25% to 35%. ACC/AHA guidelines suggest that many HF patients are discharged before optimal volume
status is achieved or sent home without the benefit of life saving therapies, which perpetuates the quick
readmission of such patients.[14] A hospital pharmacist should be an advocate for patients in the discharge
support team by assisting with medication reconciliation, discontinuing contraindicated medications, and
recommending evidence-based HF pharmacotherapy. Medications should be initiated as soon as possible, ideally
in the hospital setting; the initiation of these drugs may exacerbate HF symptoms precipitating ADHF, which
further highlights the importance of timely follow-up for this patient population.
Conclusion
ADHF is a burden to patients, health care providers, and payers. The pharmacotherapy for ADHF has not changed
recently, but the utilization of discharge support teams and rapid follow-up after discharge provide opportunities for
pharmacist intervention, both in and out of the hospital. Community pharmacists can play a large role in the
continuity of care, helping transition patients from hospital to primary care. Pharmacists are poised to offer proper
guideline-based recommendations, assist with medication reconciliation, and provide discharge education. With
the recent changes in CMS reimbursement, pharmacists need to take a larger role in the treatment of this chronic
disease.
References
1. Winslow R, Wang SS. Heart failure puts fewer in the hospital. Wall Street Journal. October 19, 2011.
http://online.wsj.com/article/SB10001424052970203658804576639360226103584.html. Accessed
September 1, 2012.
7. 10/22/13 www.medscape.com/viewarticle/780685_print
www.medscape.com/viewarticle/780685_print 7/8
2. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update. A report
from the American Heart Association. Circulation. 2010;121:e46–e215.
3. Michota FA Jr, Amin A. Bridging the gap between evidence and practice in acute decompensated heart
failure management. J Hosp Med. 2008;3(suppl):S7–S15.
4. Rau J. Medicare to penalize 2,217 hospitals for excess readmissions. Kaiser Health News. August 13,
2012. www.kaiserhealthnews.org/Stories/2012/August/13/medicare-hospitals-readmissions-penalties.aspx.
Accessed September 1, 2012.
5. Chen J, Normand ST, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization
and mortality rates for Medicare beneficiaries, 1998–2008. JAMA. 2011;306:1669–1678.
6. Amin A. Who is managing acute decompensated heart failure? The need for a multidisciplinary approach. J
Hosp Med. 2008;6(suppl):S1-S6.
7. Pinto DS, Lewis S. Pathophysiology of acute decompensated heart failure. In: Basow DS, ed. UpToDate.
Waltham, MA: UpToDate; 2012.
8. Crouch MA, Didomenico RJ, Rodgers JE. Applying consensus guidelines in the management of acute
decompensated heart failure. ACPE Program #204-000-06-407-H01. Bethesda, MD: ASHP Advantage;
2007.
9. Joseph SM, Cedars AM, Ewald GA, et al. Acute decompensated heart failure: contemporary medical
management. Tex Heart Inst J. 2009;36:510–520.
10. Pinto DS, Lewis S. Evaluation of acute decompensated heart failure. In: Basow DS, ed. UpToDate.
Waltham, MA: UpToDate; 2012.
11. Forrester JS, Diamond G, Chatterjee K, et al. Medical therapy of acute myocardial infarction by application
of hemodynamic subsets. N Engl J Med. 1976;295:1356–1362.
12. Nohria A, Mielniczuk LM, Stevenson LW. Evaluation and monitoring of patients with acute heart failure
syndromes. Am J Cardiol. 2005;96:32G-40G.
13. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated
heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated
Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57–64.
14. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005
guidelines for the diagnosis and management of heart failure in adults: a report of the American College of
Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation.
2009;119;e391-e479.
15. Heart Failure Society of America. Evaluation and management of patients with acute decompensated heart
failure: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16:e134-e156.
16. Colucci W. Treatment of acute decompensated heart failure: Components of therapy. In: Basow DS, ed.
UpToDate. Waltham, MA: UpToDate; 2012.
17. Faris R, Flather MD, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev. 2012;
(1):CD003838.
18. Gheorghiade M, Filippatos G. Reassessing treatment of acute heart failure syndromes: the ADHERE
registry. Eur Heart J. 2005;7:813–819.
19. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure.